Local Metabolic Effects of Ghrelin in Skeletal Muscle and Adipose Tissue
NCT01595373 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2013-01-16
Summary
The metabolic effects of ghrelin is investigated by microdialysis technique. Subjects are healthy young men. End points are interstitial concentrations of glucose, lactate, and glycerol.
Conditions
- Healthy
Interventions
- DRUG
-
Acyl ghrelin
Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes
- DRUG
-
Placebo (Ringer acetate)
Ringer acetate 2 microliter/min for 300 minutes
Sponsors & Collaborators
-
Esben Thyssen Vestergaard
lead OTHER
Principal Investigators
-
Esben T. Vestergaard, MD PhD · University of Aarhus
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2012-09-30
- Completion
- 2013-01-31
Countries
- Denmark
Study Locations
More Related Trials
-
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.
NCT02077348 ·Status: COMPLETED ·Phase: NA
-
The Importance of Ghrelin for Glucose Metabolism After Sleeve Gastrectomy
NCT05189353 ·Status: COMPLETED ·Phase: NA
-
RYGB and the Gastric Adipose Axis
NCT01474785 ·Status: COMPLETED ·Phase: PHASE1
-
Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin
NCT00843791 ·Status: TERMINATED ·Phase: NA
-
Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans
NCT00876213 ·Status: COMPLETED
-
Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile in Healthy Male Subjects
NCT00822003 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Glucagonotropic Effect of Amino Acids in Humans
NCT05954923 ·Status: COMPLETED ·Phase: NA
-
IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations
NCT01588093 ·Status: COMPLETED ·Phase: NA
-
Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist
NCT03133741 ·Status: COMPLETED ·Phase: NA
-
Triheptanoin in Mc Ardle
NCT02919631 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Glucagon Administration on Energy Expenditure
NCT02237053 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure
NCT00264199 ·Status: COMPLETED ·Phase: NA
-
Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?
NCT03954873 ·Status: COMPLETED ·Phase: NA
-
The Effect of Glucagon on Cerebral Glucose Metabolism in Healthy Humans
NCT06877208 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Obese Human Beta-2-adrenergic Stimulation and Muscle Glucose Uptake
NCT04921306 ·Status: COMPLETED ·Phase: PHASE2
-
Acute Effects of GLP-1 on Renal Hemodynamics
NCT04337268 ·Status: COMPLETED ·Phase: NA
-
The Role of GIP and GLP-2 in Postprandial Splanchnic Blood Flow Distribution and Metabolism
NCT05391581 ·Status: COMPLETED ·Phase: NA
-
GLP-1: Acute Effects on Kidney Function in Healthy Men
NCT01333163 ·Status: COMPLETED ·Phase: NA
-
Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure.
NCT01232244 ·Status: COMPLETED
-
Microvascular Dilatation After Endogenous Induced Hyperinsulinemia
NCT00742456 ·Status: COMPLETED ·Phase: NA
-
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)
NCT06774807 ·Status: COMPLETED ·Phase: NA
-
Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury
NCT02001363 ·Status: UNKNOWN ·Phase: NA
-
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
NCT02765399 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity
NCT06845033 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition
NCT03533179 ·Status: COMPLETED ·Phase: PHASE4